Coherus Biosciences | CHRS - Ebitda

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $-44.34M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Baxter International USD 426M 36M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Fujifilm JPY 132.72B 8.92B Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Myriad Genetics USD 10.3M 4.2M Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -30.52M 6.39M Jun/2025
Zoetis USD 1.04B 87M Sep/2025